JP2024527715A - イメージング用医薬組成物 - Google Patents

イメージング用医薬組成物 Download PDF

Info

Publication number
JP2024527715A
JP2024527715A JP2023580416A JP2023580416A JP2024527715A JP 2024527715 A JP2024527715 A JP 2024527715A JP 2023580416 A JP2023580416 A JP 2023580416A JP 2023580416 A JP2023580416 A JP 2023580416A JP 2024527715 A JP2024527715 A JP 2024527715A
Authority
JP
Japan
Prior art keywords
pdexacyaninium
free form
pharmaceutical composition
pudexacyaninium
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527715A5 (cg-RX-API-DMAC7.html
Inventor
正子 齊藤
完爾 小松
伸 田草川
デルガド-エレーラ,レティシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JP2024527715A publication Critical patent/JP2024527715A/ja
Publication of JP2024527715A5 publication Critical patent/JP2024527715A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023580416A 2021-07-28 2022-07-27 イメージング用医薬組成物 Pending JP2024527715A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163226534P 2021-07-28 2021-07-28
US63/226,534 2021-07-28
PCT/IB2022/056957 WO2023007404A1 (en) 2021-07-28 2022-07-27 Pudexacianinium for nirf imaging

Publications (2)

Publication Number Publication Date
JP2024527715A true JP2024527715A (ja) 2024-07-26
JP2024527715A5 JP2024527715A5 (cg-RX-API-DMAC7.html) 2025-05-21

Family

ID=82898903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580416A Pending JP2024527715A (ja) 2021-07-28 2022-07-27 イメージング用医薬組成物

Country Status (9)

Country Link
US (1) US20240342316A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376896A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527715A (cg-RX-API-DMAC7.html)
KR (1) KR20240041952A (cg-RX-API-DMAC7.html)
CN (1) CN117715661A (cg-RX-API-DMAC7.html)
AU (1) AU2022321011A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226034A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001242A (cg-RX-API-DMAC7.html)
WO (1) WO2023007404A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024084287A1 (en) * 2022-10-21 2024-04-25 Astellas Pharma Inc. Composition for near infrared lymphatic imaging and uses and dosages therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056131B2 (en) 2010-01-28 2015-06-16 National University Corporation Mie University Indocyanine compound, synthesis method and purification method thereof, diagnostic composition using the indocyanine compound, and device for measuring biokinetics and device for visualizing circulation using the diagnostic composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOL. IMAGING BIOL., JPN6026032558, 2021, ISSN: 0005920758 *
MOL. IMAGING BIOL., vol. 25, JPN6026032557, May 2021 (2021-05-01), pages 74 - 84, ISSN: 0005920756 *
米国FDA, GUIDANCE FOR INDUSTRY, JPN6012064675, July 2005 (2005-07-01), ISSN: 0005920757 *

Also Published As

Publication number Publication date
KR20240041952A (ko) 2024-04-01
EP4376896A1 (en) 2024-06-05
AU2022321011A1 (en) 2024-01-25
WO2023007404A1 (en) 2023-02-02
CN117715661A (zh) 2024-03-15
MX2024001242A (es) 2024-02-13
CA3226034A1 (en) 2023-02-02
US20240342316A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
Wang et al. In vivo MR and fluorescence dual-modality imaging of atherosclerosis characteristics in mice using profilin-1 targeted magnetic nanoparticles
Li et al. Mesencephalic astrocyte‐derived neurotrophic factor affords neuroprotection to early brain injury induced by subarachnoid hemorrhage via activating Akt‐dependent prosurvival pathway and defending blood‐brain barrier integrity
JP5908527B2 (ja) 慢性虚血における亜硝酸塩の使用
CN110267644B (zh) 用于治疗腺样囊性癌的苯磺酰胺衍生物的医药组合物
Murase et al. Randomized, double‐blind, controlled study to evaluate safety and pharmacokinetics of single ascending doses of ASP5354, an investigational imaging product, in healthy adult volunteers
KR20180055877A (ko) 허혈성 조직으로 구리를 운반하기 위한 트리엔틴의 용도
EP3154551B1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
JP5211073B2 (ja) 子宮内膜症の治療用の薬剤
TW201121992A (en) Suppression of cancer metastasis
US20240342316A1 (en) A pharmaceutical composition for imaging
WO2024193321A1 (zh) Glyt1抑制剂在治疗器官纤维化中的应用
Wang et al. Self-assembled extracellular matrix-lipid nanoparticle composite for site-specific siRNA delivery to improve cardiac repair post-myocardial infarction
Lin et al. Molecular photoacoustic imaging for early diagnosis and treatment monitoring of rheumatoid arthritis in a mouse model
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
HK40104552A (en) Pudexacianinium for nirf imaging
WO2021093376A1 (zh) 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
TWI899198B (zh) 包含15-hepe之組成物及治療或預防血液學病症及/或相關疾病之方法
CN110404072A (zh) 抑制yap蛋白第357位酪氨酸残基磷酸化的物质在预防动脉粥样硬化中的应用
CN110548020B (zh) 亚精胺在制备治疗主动脉瘤药物方面的应用
Akarsu Hydroxychloroquine: From Pharmacological Profile to Neglected Adverse Reactions
Yang et al. Establishment of a novel rat model of different degrees of portal vein stenosis following 70% partial hepatectomy
Graham 25 Vascular Anomalies of the Head and Neck
Hao et al. Case Report: Atrial myxoma combined with hyperthyroidism in an adolescent with literature review
JP6706632B2 (ja) 半月板変性治療用組成物
CN116492447A (zh) Foxm1在制备治疗缺血性心脏病药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260731